Neovacs SA, of Paris, said it closed its €6 million (US$7.1 million) share capital increase via private placement. Proceeds will support the company's development plan for IFNalpha Kinoid, including completion of a phase IIb trial in lupus, a phase IIa trial in dermatomyositis and preclinical proof-of-concept testing in type 1 diabetes.